Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1
Islatravir is a promising new agent for both the treatment and prevention of HIV-1 infection.
Lenacapavir Resistance Analysis in a Phase 1b Clinical Proof-Of-Concept Study
In this Phase 1 study, single SC doses of LEN resulted in potent antiviral activity over 10 days ♦ Rare low-level resistance to LEN via a single mutation (Q67H) emerged only at LEN exposures below the expected exposure in Ph2/3 studies ♦ Previous in vitro characterization identified that Q67H mutation had the least impact on
Lenacapavir Resistance Analysis in a Phase 1b Clinical Proof-Of-Concept Study Read More »
Design of an in vitro biocatalytic cascade for the manufacture of islatravir
Enzyme-catalyzed reactions have begun to transform pharmaceutical manufacturing, offering levels of selectivity and tunability that can dramatically improve chemical synthesis. Combining enzymatic reactions into multistep biocatalytic cascades brings additional benefits.
Design of an in vitro biocatalytic cascade for the manufacture of islatravir Read More »
Islatravir Is Potent and Long-Lasting — and May Be Having an Identity Crisis
At the IAS Conference on HIV Science this summer, the results of a phase II, dose-ranging study of islatravir plus doravirine in treatment-naive participants were presented. Four arms were included: three featured differing dosages of islatravir, and the fourth served as a control using doravirine plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF, Truvada). Each arm had roughly
Islatravir Is Potent and Long-Lasting — and May Be Having an Identity Crisis Read More »
Will Islatravir Add Value to Current ART Options?
Three examples of agents in phase II or III development with less frequent dosing are injectable cabotegravir and rilpivirine (an INSTI + NRTI combination), injectable leronlimab (an anti-CCR5 monoclonal antibody in the same class as ibalizumab), and parenteral or subdermal islatravir (MK-8591, in a new class of nucleoside reverse transcriptase translocation inhibitors [NRTTIs]).
Will Islatravir Add Value to Current ART Options? Read More »
Islatravir: A potential PrEP & HIV drug now being tested
A new antiretroviral named islatravir is showing promise for HIV treatment, and for PrEP delivered through an under-the-skin implant.
Islatravir: A potential PrEP & HIV drug now being tested Read More »
Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential.
This study evaluates the clinical evidence to date and efficacy and challenges of cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection in selected populations.
HIV Treatments and Guidelines Offer More Options
Case reports of sustained HIV-1 remission, new drug approvals, and resistance testing provide patients with potential novel therapy approaches.
HIV Treatments and Guidelines Offer More Options Read More »
Overview of Selected Novel Drugs Approved in 2018
2018 was a record setting year for new drug approvals by the FDA. This article highlights some of the drugs that have new mechanisms of action or have indications that have not previously been available.
Overview of Selected Novel Drugs Approved in 2018 Read More »